Gingivitis - Pipeline Review, Q2 2011

Global Markets Direct, May 2011, Pages: 34

Gingivitis - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Gingivitis - Pipeline Review, Q2 2011', provides an overview of the Gingivitis therapeutic pipeline. This report provides information on the therapeutic development for Gingivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gingivitis. 'Gingivitis - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Gingivitis.
- A review of the Gingivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Gingivitis pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Gingivitis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Gingivitis pipeline depth and focus of Gingivitis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Gingivitis Overview
Therapeutics Development
An Overview of Pipeline Products for Gingivitis
Gingivitis Therapeutics under Development by Companies
Gingivitis Therapeutics under Investigation by Universities/Institutes
Mid Clinical Stage Products
Comparative Analysis
Gingivitis Therapeutics - Products under Development by Companies
Gingivitis Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Gingivitis Therapeutics Development
GlaxoSmithKline plc
Izun Pharmaceuticals Corporation
Biomedical Development Corporation.
Gingivitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Transmucosal Herbal Periodontal Patch - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pistacia Mutica - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Iocide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Camella Sinensis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PerioPatch - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Schinus terebinthifolius - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chlorhexidine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Green Propolis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Isopropylmethylphenol + Fluoride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Gingivitis, Q2 2011
Products under Development for Gingivitis – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
GlaxoSmithKline plc, 2011
Izun Pharmaceuticals Corporation, 2011
Biomedical Development Corporation., 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011

List of Figures
Number of Products under Development for Gingivitis, Q2 2011
Products under Development for Gingivitis – Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Mid Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011

Customers who bought this item also bought

• Nausea – Pipeline Review, H1 2013
• Drug Addiction – Pipeline Review, H1 2013
• Substance (Drug) Abuse – Pipeline Review, H1 2013
• Smoking Cessation – Pipeline Review, H1 2013
• Ebola Viral Infections – Pipeline Review, H1 2013
• Liver Transplantation – Pipeline Review, H1 2013
• Bone Disorders – Pipeline Review, H1 2013
• Brain Tumor – Pipeline Review, H1 2013
• Pandemic Influenza – Pipeline Review, H1 2013
• HIV / AIDS – Pipeline Review, H1 2013